Obesity, hypertension, insulin resistance, and dyslipidemia are all clusters of an entity called
“Metabolic Syndrome”. The global trends of this syndrome's incidence/prevalence continue …

ABSTRACT Introduction Direct oral anticoagulants (DOACs) have overtaken vitamin K
antagonists to become the most widely used method of anticoagulation for most indications …

This study aimed to investigate the use of Sucrose acetate isobutyrate (SAIB) and Glyceryl
monooleate (GMO) as co-formers for creating Cubosomes and SAIB-based nanodispersions …

Background: Recent guidelines suggest that, for venous thromboembolism (VTE), standard
doses of apixaban are appropriate in patients with body mass index (BMI)> 40 kg/m2 or> …

Phase III clinical trials for individual direct oral anticoagulants (DOACs) contained a limited
representation of subjects with abnormal body weight, which were mostly limited to a BMI> …

Background and aim Atrial fibrillation (AF) is the most frequently observed cardiac
arrhythmia in clinical settings. Obesity can influence the efficacy of the treatment …

Objective Through predictable pharmacokinetics—including a convenient fixed-dose
regimen, direct oral anticoagulants (DOACs) are preferred over previous treatments in …

Patients at extremes of body weight are underrepresented in randomized controlled trials of
direct-acting oral anticoagulants (DOACs). Therefore, their optimal anticoagulant treatment …

Objective: The objective of the study was to discuss the controversies surrounding the use
and dosing of direct-acting oral anticoagulants (DOACs) in obese patients recognizing the …

Introduction The clinical outcomes of direct oral anticoagulant (DOAC) dosage regimens in
morbid obesity are uncertain due to limited clinical evidence. This study seeks to bridge this …